SLC5A2 and diabetes mellitus: Since empagliflozin alleviated both cerebral microvascular and cognitive impairment in a mixed mouse model of diabetes mellitus and Alzheimer’s disease, there is mounting evidence that SGLT-2 inhibitors have neuroprotective potential (Hierro-Bujalance et al. 2020).